394 related articles for article (PubMed ID: 32112041)
1. Synaptic and cellular plasticity in Parkinson's disease.
Chu HY
Acta Pharmacol Sin; 2020 Apr; 41(4):447-452. PubMed ID: 32112041
[TBL] [Abstract][Full Text] [Related]
2. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
3. Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia.
Prescott IA; Liu LD; Dostrovsky JO; Hodaie M; Lozano AM; Hutchison WD
Neurobiol Dis; 2014 Nov; 71():24-33. PubMed ID: 25116960
[TBL] [Abstract][Full Text] [Related]
4. Dual Roles of Microglia in the Basal Ganglia in Parkinson's Disease.
Choudhury ME; Kigami Y; Tanaka J
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918947
[TBL] [Abstract][Full Text] [Related]
5. Substantia nigra control of basal ganglia nuclei.
Guatteo E; Cucchiaroni ML; Mercuri NB
J Neural Transm Suppl; 2009; (73):91-101. PubMed ID: 20411770
[TBL] [Abstract][Full Text] [Related]
6. Synaptic dysfunction in Parkinson's disease.
Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
[TBL] [Abstract][Full Text] [Related]
7. Cellular and Synaptic Dysfunctions in Parkinson's Disease: Stepping out of the Striatum.
Mallet N; Delgado L; Chazalon M; Miguelez C; Baufreton J
Cells; 2019 Aug; 8(9):. PubMed ID: 31470672
[TBL] [Abstract][Full Text] [Related]
8. Prospects of glutamate antagonists in the therapy of Parkinson's disease.
Blandini F; Greenamyre JT
Fundam Clin Pharmacol; 1998; 12(1):4-12. PubMed ID: 9523179
[TBL] [Abstract][Full Text] [Related]
9. Neuronal inhibition and synaptic plasticity of basal ganglia neurons in Parkinson's disease.
Milosevic L; Kalia SK; Hodaie M; Lozano AM; Fasano A; Popovic MR; Hutchison WD
Brain; 2018 Jan; 141(1):177-190. PubMed ID: 29236966
[TBL] [Abstract][Full Text] [Related]
10. The endocannabinoid system in Parkinson's disease.
Di Filippo M; Picconi B; Tozzi A; Ghiglieri V; Rossi A; Calabresi P
Curr Pharm Des; 2008; 14(23):2337-47. PubMed ID: 18781984
[TBL] [Abstract][Full Text] [Related]
11. Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson's disease.
Benazzouz A; Mamad O; Abedi P; Bouali-Benazzouz R; Chetrit J
Front Aging Neurosci; 2014; 6():87. PubMed ID: 24860498
[TBL] [Abstract][Full Text] [Related]
12. Glutamate receptors as therapeutic targets for Parkinson's disease.
Johnson KA; Conn PJ; Niswender CM
CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):475-91. PubMed ID: 19702565
[TBL] [Abstract][Full Text] [Related]
13. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders.
Rouse ST; Marino MJ; Bradley SR; Awad H; Wittmann M; Conn PJ
Pharmacol Ther; 2000 Dec; 88(3):427-35. PubMed ID: 11337032
[TBL] [Abstract][Full Text] [Related]
14. Anatomy of the dopamine system in the basal ganglia.
Smith Y; Kieval JZ
Trends Neurosci; 2000 Oct; 23(10 Suppl):S28-33. PubMed ID: 11052217
[TBL] [Abstract][Full Text] [Related]
15. Levodopa Effect on Basal Ganglia Motor Circuit in Parkinson's Disease.
Gao LL; Zhang JR; Chan P; Wu T
CNS Neurosci Ther; 2017 Jan; 23(1):76-86. PubMed ID: 27663605
[TBL] [Abstract][Full Text] [Related]
16. Synaptic dysfunction in Parkinson's disease.
Picconi B; Piccoli G; Calabresi P
Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
[TBL] [Abstract][Full Text] [Related]
17. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
Obeso JA; RodrÃguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
[TBL] [Abstract][Full Text] [Related]
18. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains.
Smith Y; Villalba R
Mov Disord; 2008; 23 Suppl 3():S534-47. PubMed ID: 18781680
[TBL] [Abstract][Full Text] [Related]
19. Functional changes of the basal ganglia circuitry in Parkinson's disease.
Blandini F; Nappi G; Tassorelli C; Martignoni E
Prog Neurobiol; 2000 Sep; 62(1):63-88. PubMed ID: 10821982
[TBL] [Abstract][Full Text] [Related]
20. Glutamate and Parkinson's disease.
Blandini F; Porter RH; Greenamyre JT
Mol Neurobiol; 1996 Feb; 12(1):73-94. PubMed ID: 8732541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
